515 Uploads

Roche’s Glofitamab
Roche’s Glofitamab
  • 22 views
Braftovi shows a higher response rate in a triplet combination after adding Opdi
Braftovi shows a higher response rate in a triplet combination after adding Opdi
  • 14 views
Closely watched Janssen and Legend Biotech's CAR-T cell therapy
Closely watched Janssen and Legend Biotech's CAR-T cell therapy
  • 21 views
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R f
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R f
  • 46 views
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic
Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic
  • 13 views
Enhertu carving out a new space for itself in HER2 low patients
Enhertu carving out a new space for itself in HER2 low patients
  • 27 views
ASCO 2022 Conference
ASCO 2022 Conference
  • 15 views
Newly Launched First in Class LAG-3 Combination Drug Opdualag
Newly Launched First in Class LAG-3 Combination Drug Opdualag
  • 45 views
Encouraging results of nivolumab bevacizumab FOLFOXIRI
Encouraging results of nivolumab bevacizumab FOLFOXIRI
  • 16 views
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise
  • 19 views
Vasomotor symptoms (Hot flashes/Night sweats) Infographics
Vasomotor symptoms (Hot flashes/Night sweats) Infographics
  • 16 views
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-
Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-
  • 20 views
Primary Hyperoxaluria Market Insight, Epidemiology And Market Forecast - 2032
Primary Hyperoxaluria Market Insight, Epidemiology And Market Forecast - 2032
  • 10 views
The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care
The PROs Further Support Durvalumab Chemo in Becoming The New Standard of Care
  • 14 views
Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)
Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)
  • 11 views
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Sta
Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Sta
  • 17 views
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market
  • 16 views
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For
With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For
  • 15 views
Chronic Lower Back Pain Infographic Market Infographic
Chronic Lower Back Pain Infographic Market Infographic
  • 26 views
Is there enough opportunity in the competitive therapeutic landscape of Multiple
Is there enough opportunity in the competitive therapeutic landscape of Multiple
  • 20 views
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In
  • 34 views
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC
  • 12 views
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic H
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic H
  • 16 views
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR
  • 10 views
Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032
Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032
  • 11 views
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
Mimivax’s SurVaxM Improves Survival Time In Newly Diagnosed Glioblastoma
  • 10 views
What is the Multiple Sclerosis?
What is the Multiple Sclerosis?
  • 11 views
Newly Diagnosed Glioblastoma
Newly Diagnosed Glioblastoma
  • 13 views
With the emergence of Next-generation SERDs, Sanofi might hit the mark
With the emergence of Next-generation SERDs, Sanofi might hit the mark
  • 11 views
Elranatamab exhibits a 60.6% ORR and a tolerable safety profile
Elranatamab exhibits a 60.6% ORR and a tolerable safety profile
  • 20 views
What is the Common Warts?
What is the Common Warts?
  • 8 views
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed i
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed i
  • 17 views
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial
Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial
  • 18 views
Is GSK's Jemperli giving us reason to believe that cancer can be beaten? It's in
Is GSK's Jemperli giving us reason to believe that cancer can be beaten? It's in
  • 10 views
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced P
CEL-SCI Corporation Presents First-of-its-Kind Results For Lower-Risk Advanced P
  • 7 views
ASCO Conference 2022- Breast Cancer
ASCO Conference 2022- Breast Cancer
  • 86 views
ASCO 2022 Conference
ASCO 2022 Conference
  • 84 views
Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R F
Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R F
  • 25 views
ASCO 2022 Conference
ASCO 2022 Conference
  • 17 views
Neurofibromatosis Newsletter
Neurofibromatosis Newsletter
  • 10 views